sectionOne-bg
sectionOne-bg

This is a healthcare professional site

The information contained in the site is intended for US healthcare professionals only. By selecting “Okay” below, you verify that you are a licensed US healthcare professional.

By selecting "Okay" below, you verify that you are a licensed US healthcare professional.

sectionOne-bg
sectionOne-bg
sectionOne-bg_image
sectionOne-bg_image

Discover Claudin18.2,
 a novel biomarker in the advanced gastric cancer landscape.

SCROLL TO EXPLORE SCROLL TO EXPLORE
cloud image
cloud image

Despite a landscape clouded in complexity, emerging biomarkers are expanding our view of patient populations, and biomarker testing could provide a more comprehensive patient profile.

 

Exploring biomarker advancements starts here.
SCROLL TO EXPLORE
landscape_image
landscape_image
WELCOME TO

The Gastric Cancer Landscape

SELECT A BIOMARKER BELOW

CLDN18.2=Claudin18.2; FGFR2b=fibroblast growth factor receptor 2, isoform IIIb; HER2=human epidermal growth factor receptor 2; MSI=microsatellite instability; PD-L1=programmed death-ligand 1.

SCROLL TO EXPLORE

AN UNMET NEED

Despite recent advances, there are still critical needs to address in gastric/gastroesophageal junction (G/GEJ) cancers

 

In the United States, approximately 6% of patients with metastatic G/GEJ cancer survive 5 years post diagnosis.1,2*†

Approximately 6% 5-year survival rate of metastatic gastric/gastroesophageal junction (mG/GEJ) cancer in the US.

*US SEER 22 areas (2013-2019), gastric and esophageal cancers, distant stage.1,2

†SEER data do not have a separate classification for GEJ apart from esophageal cancer; therefore, true GEJ projections are unknown.2

IN THE UNITED STATES

In 2023, an estimated 26,500 new cases of gastric cancer (62% advanced‡ stage) and ~21,600 new cases of esophageal† cancer (72% advanced‡ stage) will be diagnosed in the US.1-3

In the US, patients with advanced disease at diagnosis will likely have a poor outcome,4,5 and less than 50% will receive second-line therapy for mG/GEJ cancer.6§

‡Locally advanced (stage II and III) and metastatic (stage IV) gastric/GEJ cancer per tumor node metastases (TNM) staging classification as described in NCCN Guidelines.4,5

§Data from a retrospective analysis of electronic medical records of 3850 eligible G/GEJ/esophageal adenocarcinoma patients that underwent first-line therapy and were alive at 45 days after completion of first-line therapy.6

TNM=tumor node metastases.

AROUND THE WORLD

Over 1.6 million new cases of gastric and esophagealII cancers were diagnosed worldwide in 2020, making them the 5th and 7th most diagnosed cancers, respectively.7

An estimated 1.3 million people died worldwide in 2020 due to gastric and esophagealII cancers, making them the 4th and 6th most deadly
cancers, respectively.7

 

IIBased on GLOBOCAN 2020 data for gastric and esophageal cancers. GLOBOCAN data do not have a separate classification for GEJ apart from esophageal cancer; therefore, true GEJ projections are unknown.7

As novel biomarkers emerge, they may reveal more opportunities to enhance care for advanced G/GEJ cancer

 

EMERGING BIOMARKERS

help identify previously undefined subsets of patients:

  • CLDN18.2 , as a component of tight junctions, has a role in the regulation of permeability, barrier function, and polarity of epithelial layers8-10
  • FGFR2b is a splice variant of FGFR2, a transmembrane signaling pathway that intermediates diverse cellular behaviours and processes, such as mitogenesis, differentiation, cell proliferation, angiogenesis, and invasion11,12

ESTABLISHED BIOMARKERS

are used to inform clinical decisions:

  • HER2 is associated with activation of downstream signaling that leads to uncontrolled cell-cycle progression, cell division and proliferation, motility, invasion, and adhesion13
  • MSI is characterized by the accumulation of mutations in microsatellite DNA sequences leading to genomic instability.11,14 MSI occurs when the DNA MMR system does not function appropriately14
  • PD-L1 can bind to the immune checkpoint receptor PD-1 (programmed death cell protein 1) which allows tumors to escape immune surveillance15

CLDN18.2=Claudin18.2; FGFR2b=fibroblast growth factor receptor 2, isoform IIIb; HER2=human epidermal growth factor receptor 2; MMR=mismatch repair; MSI=microsatellite instability; PD-L1=programmed death-ligand 1.

CLDN18.2
(Claudin18.2)

CLDN18.2 gastric cancer biomarker.

CLDN18.2

CLDN18.2 is an emerging biomarker that may help you learn more about your patients with advanced G/GEJ cancer16



Claudins are a family of transmembrane proteins8:

Claudins are a major component of tight junctions, which are involved in controlling the flow of molecules between cells.8,9

Claudins are present throughout the body, but two specific isoforms of CLDN18 are localized to certain tissue types8,17:

  • CLDN18.2 is the dominant isoform in normal gastric tissue and is often retained in malignant transformation
  • CLDN18.1 is the dominant isoform in normal and malignant lung tissue

 

Preclinical data have shown that CLDN18.2 may become more exposed
 as gastric tumors develop.8,16

CONFINED IN HEALTHY TISSUE

CLDN18.2 confined in healthy tissue.
CLDN18.2 confined in healthy tissue.

In normal gastric mucosa, CLDN18.2 is typically buried within tight junctions8,16

RETAINED AND EXPOSED IN MALIGNANT TRANSFORMATION

CLDN18.2 retained and exposed during malignant transformation.
CLDN18.2 retained and exposed during malignant transformation.

CLDN18.2 is often retained during malignant transformation.

CLDN18.2 may be more exposed when cell polarity disruptions and structure loss occur.8,16,18

MAINTAINED IN METASTATIC PROGRESSION

CLDN18.2 maintained in metastatic progression.
CLDN18.2 maintained in metastatic progression.

CLDN18.2 may also be localized in lymph node metastases of gastric adenocarcinoma as well as other distant metastatic sites.8,19-21

The information provided above is based on the current understanding of data.

 

CLDN18.2 expression may also be observed in esophageal adenocarcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, and ovarian mucinous adenocarcinoma.8

Detecting the presence of CLDN18.2 identifies a previously undefined patient population

 

While approximately 70% of advanced G/GEJ cancers express CLDN18.2 (at any detectable amount),20* two recent studies have shown that approximately 38% of patients with locally advanced unresectable or mG/GEJ cancer are Claudin18.2 positive (≥75% of tumor cells demonstrating moderate to strong membranous CLDN18 staining by IHC).22,23†

  • Among advanced G/GEJ biomarkers, CLDN18.2 is highly prevalent13,22-24
  • Detecting CLDN18.2 can be accomplished by standard IHC staining methods, as with many other biomarkers22-25

*Data from a retrospective analysis of 350 Caucasian patients with advanced G/GEJ cancer.20
†Data from 2 global randomized Phase 3 studies: the first study included 2,403 assessable patients, of which 922 were CLDN18.2 positive; and a second study which included 2,104 assessable patients, of which 808 were CLDN18.2 positive.22,23
‡Any detectable amount: moderate to strong membranous CLDN18 staining by immunohistochemistry (IHC) in any percentage of tumor cells.20

CLDN18.2 is highly prevalent among biomarkers for advanced G/GEJ cancer.13,22-24

Biomarker prevalence estimates from select studies are reported below. Prevalence data can vary among studies due to tumor heterogeneity, differences in patient population, clinical trial methodology, and diagnostic assays used. Positivity thresholds also vary by study.13,22-24,26-28

EMERGING BIOMARKERS

CLDN18.222,23
(positive)§

38%

FGFR2b26||
(positive)

30%

§≥75% of tumor cells demonstrating moderate to strong membranous CLDN18 staining by IHC.22,23
||FGFR2b positivity: FGFR2b overexpression (IHC 2+/3+ any amount of tumor cells) and/or FGFR2 gene amplification by ctDNA (NGS 1.5x increase in FGFR2).26

ESTABLISHED BIOMARKERS

PD-L124,27
(variable due to multiple factors)

CPS ≥1: 67-73%
CPS ≥5: 29-31%
CPS ≥10: 16-18%

HER213
(positive)

22%

MSI28
(MSI-high)

4%

CPS=combined positive score.
PD-L1 prevalence at various CPS thresholds is still being explored. Data are from a randomized controlled trial and a real-world retrospective medical records study.24,27

CLDN18.2 is detected via IHC, as is standard with many other biomarkers22-25

 

EMERGING BIOMARKERS

CLDN18.2:
IHC22,23

FGFR2b:
IHC, NGS (ctDNA)26#

#FGFR2b protein overexpression assessed by IHC; FGFR2 gene amplification assessed using ctDNA by NGS.26

 

ESTABLISHED BIOMARKERS

PD-L1:
IHC4,5**

HER2:
IHC, ISH, NGS4,5,25††

MMR/MSI:
IHC, PCR/NGS4,5‡‡

 

ctDNA=circulating tumor DNA; IHC=immunohistochemistry; ISH=in situ hybridization; NGS=next generation sequencing; PCR=polymerase chain reaction.
** Varying diagnostic assays.29
†† Other ISH methods (FISH=fluorescent ISH; SISH=silver ISH; CISH=chromogenic ISH; DDISH=dual-color dual-hapten ISH).25
‡‡ MMR assessed by IHC, MSI by PCR/NGS.4,5


IHC scoring for CLDN18 in G/GEJ cancer is performed based on membrane staining intensity and percent of positive tumor cells22,23,30

Membrane staining of tumor cells for "0 No Staining," "1+ Weak Staining," "2+ Moderate Staining," and "3+ Strong Staining."
Membrane staining of tumor cells for "0 No Staining," "1+ Weak Staining," "2+ Moderate Staining," and "3+ Strong Staining."

CLDN18.2 positivity is defined as ≥75% of tumor cells demonstrating moderate to strong membranous CLDN18 staining by IHC.22,23

CLDN18.2 expression has been seen in both diffuse-type gastric tumors and intestinal-type gastric tumors.20

  • Tumors with diffuse histology, as seen in the US and other Western countries, are associated with a poorer prognosis than those with intestinal histology31

FGFR2b
(fibroblast growth factor receptor 2b, isoform lllb)

FGFR2b gastric cancer biomarker.

FGFR2b

FGFR2b is an emerging biomarker that introduces another way to identify a subset of patients with advanced G/GEJ cancer12

 

FGFR2b participates in angiogenesis and cell proliferation through
FGFR signaling pathways.11,12

  • FGFR2 (fibroblast growth factor receptor 2) is a receptor tyrosine kinase that has a role in normal cell development32
  • The splice variant FGFR2b is expressed in various types of epithelial cells where tumors may begin to grow (including pancreatic, breast, endometrial, cervical, lung, and colorectal cancers)32,33
  • FGFR2b may be associated with higher T stage (size of the tumor and any spread into nearby tissue) and higher N stage (extent of nodal metastases)12,34

 

FGFR2b positivity has been observed in 30% of advanced G/GEJ cancers.26*


FGFR2b positivity: FGFR2b overexpression (IHC 2+/3+ any amount of tumor cells) and/or FGFR2 gene amplification by ctDNA (NGS 1.5x increase in FGFR2)
*Data from select studies.26

 

 

Detecting FGFR2b can be done with the following tests26:

  • FGFR2b overexpression using IHC
  • FGFR2 gene amplification using ctDNA by NGS

 

HER2
(human epidermal growth factor receptor 2)

HER2 gastric cancer biomarker.

HER2

HER2 was the first biomarker used to guide clinical decisions in advanced G/GEJ cancer11



HER2 (human epidermal growth factor receptor 2) is a receptor-tyrosine kinase that is overexpressed and/or amplified in advanced G/GEJ cancer.11

HER2 is a proto-oncogene that is involved in signaling pathways, which leads to cell growth and differentiation.25

  • Studies have shown HER2 is present in several cancers, including colorectal, ovarian, prostate, and lung tumors25
  • When HER2 is overexpressed and/or amplified, it can lead to uncontrolled cell growth and tumorigenesis13:

    • However, the mechanisms that lead to gene amplification remain largely unknown35

 

HER2 positivity has been reported in 22% of advanced G/GEJ cancers.13*



HER2 positivity: overexpression (IHC3+) and/or gene amplification (FISH-positive)
*Data from select studies.13


Detection of HER2 may be done with IHC, NGS, and ISH methods.4,5

  • Guidelines recommend starting with IHC; followed by ISH methods only when IHC expression is 2+ (equivocal)4,5

    • IHC/ISH should be considered first, followed by additional NGS testing as appropriate4,5
    • ISH methods include fluorescent in situ hybridization (FISH), silver in situ hybridization (SISH), chromogenic in situ hybridization (CISH), and dual-color dual-hapten in situ hybridization (DDISH)25
  • Positive (3+) or negative (0 or 1+) IHC results do not require further testing via ISH4,5
  • HER2 testing in gastric cancer differ from testing in breast cancer due to differences in tumor biology, intratumoral heterogeneity of HER2 expression, and incomplete membrane staining13,25
  • Overexpression or amplification of HER2 is more common in patients with intestinal histology13

MSI
(microsatellite instability)

MSI gastric cancer biomarker.

MSI

MSI is an established biomarker that can be found in a broad range of solid tumor types, including advanced G/GEJ cancer14



MSI is associated with genomic instability and increased susceptibility to tumor development.11

Microsatellites are repeated sequences of nucleotides in DNA.14

  • Microsatellite instability (MSI) is caused when the DNA mismatch repair (MMR) system is not functioning appropriately14:

    • This loss prevents normal repair and correction of DNA, allowing mismatches to occur14
    • The MMR proteins are the most frequently mutated genes in cancer14
  • Tumors with ≥30% expression of unstable microsatellites are referred to as MSI-high (MSI-H), while tumors with 10-29% expression are considered MSI-low11
  • MSI is found most often in colorectal cancer, gastric cancer, and endometrial cancer, but it may also be found in many other types of cancer14

 


MSI-H has been reported in 4% of advanced G/GEJ cancers.28*

*Data from select studies.28




Detection of MSI and MMR is typically assessed with various methods.4,5

  • MSI gene expression can be detected via PCR-based molecular testing and NGS
  • MMR protein expression can be analyzed via IHC

PD-L1
(programmed death-ligand 1)

PD-L1 gastric cancer biomarker.

PD-L1

Among biomarkers in advanced G/GEJ cancer, PD-L1 is one of the more recent to be utilized in clinical decision-making36



PD-L1 (programmed death-ligand 1) is a transmembrane protein that may be expressed on various tumor cells and/or immune cells.37

  • When bound to PD-1, PD-L1 acts as a T-cell inhibitory molecule, leading to immune cell evasion and subsequent tumor cell survival37
  • PD-L1 expression has been detected in various tumors, including lung, colon, ovarian, and gastric cancers38
  • However, the cellular process of expression may not always be the same throughout the body39

    • Various studies have shown discordant levels of PD-L1 in the primary tumor vs metastatic lesions39

 

Prevalence of PD-L1 has been reported for several positivity thresholds throughout various studies24,27*:

PD-L1 prevalence at various CPS thresholds is still being explored. Data are from a randomized controlled trial and a real-world retrospective medical records study.24,27
*Data from select studies.24,27

 

  • The variations in prevalence may be due to several factors, such as tumor heterogeneity and clinical trial methodology (including differences in patient population, staining techniques, scoring algorithms, and diagnostic assays)39,40
  • Expression levels may also vary during disease progression, as PD-L1 is impacted by changes in immune response39

PD-L1 expression is detected using IHC.4,5

CPS=combined positive score.

SUMMARY

Initial diagnostic panels with biomarker testing may lead to more comprehensive patient profiles and informed clinical decisions

 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer and Esophageal and Esophagogastric Junction Cancers* support using biomarkers to help map the path forward for patients.4,5†

  • Biomarker testing has an important role in the diagnosis, classification, and molecular characterization of G/GEJ cancer
  • The implementation of molecular testing has had a significant impact on clinical practice and patient care


The NCCN Guidelines® recommend4,5:

  • Testing for all established biomarkers (HER2, MSI, PD-L1) at diagnosis if metastatic cancer is documented or suspected
  • The use of IHC/ISH/targeted PCR should be considered first, followed by additional NGS testing as appropriate

*In adenocarcinomas of unresectable locally advanced, locally recurrent or metastatic disease of esophageal and esophagogastric junction cancers.5
†This is a summary of relevant portions of the NCCN Guidelines. Please see the full NCCN Guidelines for Gastric Cancer and Esophageal and Esophagogastric Junction Cancers at NCCN.org.4,5


Biomarker testing provides more insight into advanced G/GEJ cancer as more biomarkers are discovered.

  • Standard IHC staining methods can detect a wide range of emerging and established biomarkers

    • IHC can detect CLDN18.2, FGFR2b, PD-L1, HER2, MMR4,5,22,23,26
    • Other testing methods often focus on specific biomarkers (ctDNA by NGS for FGFR2, ISH/NGS for HER2,‡ and PCR/NGS for MSI)4,5,26

      • ‡The use of IHC/ISH/targeted PCR should be considered first, followed by additional NGS testing as appropriate.4,5

  • According to recent studies, biomarker testing has revealed a high prevalence of emerging biomarkers

    • Approximately 38% of patients with locally advanced unresectable or mG/GEJ cancer were CLDN18.2 positive22,23
    • 30% of advanced G/GEJ cancers observed FGFR2b positivity26§
  • Prevalence of established biomarkers have been reported throughout various studies as:

    • HER2 positivity in 22% of advanced G/GEJ cancers13§
    • MSI-H in 4% of advanced G/GEJ cancers28§
    • PD-L1 at several positivity thresholds: 67-73% CPS ≥1, 29-31% CPS ≥5, and 16-18% CPS ≥1024,27§

§Data from select studies. Prevalence data can vary among studies due to tumor heterogeneity, differences in patient populations, clinical trial methodology, and diagnostic assays used. Positivity thresholds may vary by study.13,24,26-28

As biomarker research continues, it expands our view of the patient population, reveals more information about the advanced G/GEJ cancer landscape, and helps inform clinical decisions.

Astellas Answers logo.

Have a question?

Find answers at
astellasanswers.com.

ASK OUR MEDICAL INFORMATION TEAM

Download a PDF about the biomarker advancements in advanced G/GEJ cancers.

DOWNLOAD PDF

Stay up to date

By signing up below, you will receive updates about emerging biomarkers in advanced G/GEJ cancer. You may also be contacted by an Astellas representative. Please note that fields marked with (*) are required.


Thank you for signing up!

You will now receive email updates about emerging biomarkers in mG/GEJ cancer, and you may be contacted by an Astellas representative.

REFERENCES

  1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: stomach cancer. https://seer.cancer.gov/statfacts/html/stomach.html. Accessed 04-24-2023.
  2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: esophageal cancer. https://seer.cancer.gov/statfacts/html/esoph.html. Accessed 05-11-2023.
  3. American Cancer Society. Cancer Facts & Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. Accessed 01-19-2023.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 13, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 13, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.
  6. Barzi A, Hess LM, Zhu YE, et al. Real-world outcomes and factors associated with the second-line treatment of patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Cancer Control (Epub) 05-06-2019.
  7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49.
  8. Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008;14(23):7624-34.
  9. Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci 2019;44(2):141-52.
  10. Hu YJ, Wang YD, Tan FQ, Yang WX. Regulation of paracellular permeability: factors and mechanisms. Mol Biol Rep 2013;40(11):6123-42.
  11. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective. World J Gastroenterol 2018;24(26):2818-32.
  12. Ahn S, Lee J, Hong M, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol 2016;29(9):1095-103.
  13. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18(3):476-84.
  14. Baudrin LG, Deleuze JF, How-Kit A. Molecular and computational methods for the detection of microsatellite instability in cancer. Front Oncol (Epub) 12-12-2018.
  15. Kawazoe A, Shitara K, Kuboki Y, et al. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer 2019;22(1):69-76.
  16. Sahin U, Schuler M, Richly H, et al. Eur J Cancer 2018;100:17-26.
  17. Niimi T, Nagashima K, Ward JM, et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 2001;21(21):7380-90.
  18. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15(3):178–96.
  19. Coati I, Lotz G, Fanelli GN, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer 2019;121(3):257-63.
  20. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021.
  21. Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol 2019;49(9):870-6.
  22. Shitara K, Lordick F, Bang YJ, et al. Lancet 2023 Apr 14:S0140-6736(23)00620-7.
  23. Xu RH, Shitara K, Ajani JA, et al. #405736. Presented at: March American Society of Clinical Oncology Plenary Series; March 22, 2023.
  24. Fuchs CS, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer (Epub) 09-01-2021.
  25. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol 2016;22(19):4619-25.
  26. Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastrooesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2022;23(11):1430-40.
  27. Schoemig-Markiefka B, Eschbach J, Scheel AH, et al. Optimized PD-L1 scoring of gastric cancer. Gastric Cancer 2021;24(5):1115-22.
  28. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):e180013. Erratum in: JAMA Oncol 2019;5(4):579.
  29. Yeong J, Lum HYJ, Teo CB, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022;25(4):741-50.
  30. Supplement to: Sahin U, Türeci Ö, Manikhas G, et al. Ann Oncol 2021;32(5):609-19.
  31. Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: East vs. West. J Gastric Cancer 2012;12(2):55-62. Erratum in: J Gastric Cancer 2012;12(4):262.
  32. Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y, Naito Z. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol Rep 2004;11(5):987-91.
  33. Matsuda Y, Ueda J, Ishiwata T. Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog Res Int (Epub) 06-04-2012.
  34. National Cancer Institute. NCI dictionary of cancer terms: TNM staging system. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tnm-staging-system. Accessed 07-13-2022.
  35. Vicario R, Peg V, Morancho B, et al. Patterns of HER2 gene amplification and response to anti-HER2 therapies. PLoS One (Epub) 06-15-2015.
  36. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34.
  37. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol (Epub) 08-27-2019.
  38. Qing Y, Li Q, Ren T, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther 2015;9:901-9.
  39. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 2015;41(10):868-76.
  40. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40.



BACK

Terms of Use

The information provided on gastriccancerbiomarkers.com is intended for residents of the United States.
© 2023 Astellas Pharma US, Inc. All rights reserved.

WEBSITE TERMS OF USE (Effective date: 4/22)

 

ATTENTION: PLEASE READ THESE TERMS CAREFULLY BEFORE USING THIS WEBSITE GASTRICANCERBIOMARKERS.COM. BY USING THIS SITE, INCLUDING ANY SERVICES PROVIDED ON OR THROUGH THIS SITE GASTRICANCERBIOMARKERS.COM, YOU INDICATE THAT YOU ACCEPT THESE TERMS. IF YOU DO NOT ACCEPT THESE TERMS, DO NOT USE THIS SITE.

 

Astellas Pharma US, Inc., (Astellas) may at any time revise these Terms of Use by updating this posting, so you should periodically examine the current Terms of Use to which you are bound. Certain provisions of these Terms of Use may be superseded by expressly designated legal notices or terms located on particular pages at this Site. To view the Terms of Use at any time, go to GastricCancerBiomarkers.com.

GENERAL INFORMATION. This Site contains information that may be of interest to members of the healthcare community. Please feel free to browse this Site and Services. Your access and use of the Site are subject to the following terms and conditions, and all applicable laws. By accessing and browsing this Site and Services, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Astellas.

PRIVACY. Astellas's policies concerning the use of your personal information are set forth in Astellas's Privacy Policy, which you can find by clicking here, and which are incorporated by reference herein. By using this Site or any services provided by or through this Site (Services), you agree to waive and release Astellas from any claim or liability in connection with the collection, use, or disclosure of information consistent with Astellas's Privacy Policy.

SITE CONTENT. All material on the Site including, but not limited to, text, images, graphics, documents, audio, or video (collectively, the Site Content) are protected under applicable copyright laws. You may copy, download, or print Site Content for your personal, noncommercial purposes only, but no modification or further reproduction of content is permitted. The Site Content may not otherwise be copied, downloaded, reproduced, deleted, modified, republished, retransmitted, displayed, or used to create derivative works without the express written permission of Astellas.

Trademarks, service marks, trade dress, logos, designs, and slogans appearing on this Site are owned by Astellas, its Affiliate companies, its licensors, or its partners, and may not be used for advertising or publicity purposes, or to indicate any affiliation with or endorsement by Astellas, except with the express written permission of Astellas.

Nothing contained in this Site should be construed as granting a license to, or right in, any trademarks, patents, or copyrights of Astellas, or any other party.

You are solely responsible for any content, including but not limited to text, photographs, caricatures, illustrations, designs, icons, articles, audio clips, and video clips (collectively, User Content) that you post, email, or otherwise transmit via this Site. Astellas does not own or endorse User Content posted or otherwise transmitted via this Site, and Astellas does not guarantee the accuracy, integrity, or quality of such User Content. Any communications you send via this Site or otherwise to Astellas by email, with the exception of personally identifiable information as defined in Astellas's Privacy Policy, shall be deemed to be nonconfidential and Astellas shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation. Astellas shall be free to use any ideas, concepts, know-how, or techniques contained in such information for any purpose whatsoever, including but not limited to developing, manufacturing, and marketing activities incorporating such information.

The content or material Astellas provides through the Site is for informational purposes only. Nothing on this Site should be construed as the giving of advice (medical, legal, financial, investment, or other professional advice) or the making of a recommendation, and information on the Site should not be relied on as the basis for any decision or action. IT IS IMPORTANT THAT YOU RELY ONLY ON THE ADVICE OF A HEALTHCARE PROFESSIONAL TO ADVISE YOU ON YOUR SPECIFIC SITUATION. YOU SHOULD NEVER DISREGARD OR DELAY SEEKING MEDICAL ADVICE BECAUSE OF SOMETHING THAT YOU HAVE SEEN ON THIS SITE.

OBLIGATIONS OF SITE VISITORS OR USERS. You agree not to do any of the following while visiting or using the Site or any services provided by or through this Site:

  • Impersonate or misrepresent your affiliation with any person or entity;
  • Except as expressly permitted by the rules of this Site, post or transmit any unsolicited advertising, promotional materials, (junk mail), (spam), (chain letters), or any other form of solicitation on the Site or through the Services;
  • Post or transmit any information or material that is defamatory, offensive, indecent, obscene, or unlawful;
  • Post or transmit any information or software which contains a virus, Trojan horse, worm, or other harmful components;
  • Violate any applicable law or regulation, including without limitation any local, state, provincial, national or international law, any export control laws, or any regulations promulgated by any state or federal authority;
  • Access or use password-protected, secure or nonpublic areas of the Site without authorization; or
  • Frame, repackage, or otherwise redistribute any portion of the Site.

Astellas may, in its sole discretion, take any action it deems necessary, including but not limited to termination of access to the Site or modification of User Content, if Astellas believes a user's conduct or content fails to conform to these Terms of Use or may create liability for Astellas, its partners, its suppliers, or any other party or person. Astellas will not be liable to you or any third party as a result of such termination or modification. The terms and conditions provided in these Terms of Use will survive any such termination and modification.

LINKS TO OTHER WEBSITES. Solely as a convenience to you, Astellas may provide links on this Site to other websites that are not maintained by or under the control of Astellas. If you use these links, you will leave this Site. Please remember that linked sites are not necessarily Astellas's sites, and the information could change without Astellas's knowledge. Third-party linked sites and their contents should not be attributed to Astellas (or any of its affiliated companies) in any manner. Astellas has not attempted to verify the truth or accuracy of any third-party sites or content contained on any third-party sites and does not make any representations or warranties about such sites or the content of such sites. If you decide to access any of the third-party sites linked to this Site, you do so entirely at your own risk. In the event Astellas endorses a particular organization, Astellas will clearly state its endorsement next to any link to that organization.

DISCLAIMER OF WARRANTIES. THIS SITE, INCLUDING ANY INFORMATION, SERVICES, OR MATERIAL MADE AVAILABLE ON OR THROUGH THIS SITE, IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. TO THE MAXIMUM EXTENT PERMITTED BY LAW, ASTELLAS EXPRESSLY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. FURTHERMORE, ASTELLAS DOES NOT WARRANT THE ACCURACY OR COMPLETENESS OF ANY INFORMATION ON THIS SITE AND MAY MAKE CHANGES TO THE INFORMATION, SERVICES, OR MATERIAL MADE AVAILABLE ON OR THROUGH THIS SITE AT ANY TIME WITHOUT PRIOR NOTICE TO USERS OF THIS SITE. INFORMATION AT THIS SITE THAT IS PERIODICALLY UPDATED MAY NOT BE CURRENT AT THE MOMENT YOU VISIT THIS SITE AND MAY CONTAIN ERRORS. ASTELLAS MAKES NO WARRANTY THAT THE SITE WILL MEET YOUR REQUIREMENTS; THAT THE SITE WILL BE UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE; THAT MESSAGES OR REQUESTS WILL BE DELIVERED; THAT DEFECTS WILL BE CORRECTED; OR THAT THIS SITE IS FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ASTELLAS MAKES NO WARRANTY REGARDING ANY GOODS OR SERVICES PURCHASED OR OBTAINED THROUGH THE SITE OR ANY TRANSACTIONS ENTERED INTO THROUGH THE SITE. YOU ASSUME THE ENTIRE RISK AS TO THE RESULTS AND PERFORMANCE OF THE SITE AND ANY GOODS OR SERVICES PURCHASED THEREFROM.

LIMITATION OF LIABILITY. IN NO EVENT WILL ASTELLAS BE LIABLE FOR ANY DAMAGES WHATSOEVER. THIS INCLUDES BUT IS NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, THOSE RESULTING FROM LOST PROFITS, LOST DATA, OR BUSINESS INTERRUPTION) ARISING OUT OF THE USE, INABILITY TO USE, OR THE RESULT OF USE OF THIS SITE, ANY WEBSITES LINKED TO THIS SITE, THE MATERIALS OR INFORMATION CONTAINED ON ANY OR ALL SUCH SITES, OR ANY MATERIALS, PRODUCTS, OR SERVICES OFFERED ON THIS SITE OR SITES LINKED TO THIS SITE, WHETHER BASED ON WARRANTY, CONTRACT, TORT, OR ANY OTHER LEGAL THEORY AND WHETHER OR NOT ADVISED ON THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT WILL ASTELLAS, ITS SUPPLIERS, OR ANY OTHER PARTY INVOLVED IN CREATING, PRODUCING, OR DELIVERING THIS SITE BE LIABLE TO YOU IN ANY MANNER WHATSOEVER FOR ANY DECISION MADE OR ACTION OR NONACTION TAKEN BY YOU IN RELIANCE UPON INFORMATION PROVIDED THROUGH THIS SITE. APPLICABLE LAW MAY NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY TO YOU.

THIS SITE IS INTENDED FOR US AUDIENCES ONLY. Access to and use of this Site is subject to the above terms and conditions. This Site was developed and is maintained by Astellas. Information, copy, and claims are intended only for the residents of the United States.